HRP20161158T1 - Interferon beta za liječenje bolesti donjeg dišnog sustava izazvane gripom - Google Patents
Interferon beta za liječenje bolesti donjeg dišnog sustava izazvane gripom Download PDFInfo
- Publication number
- HRP20161158T1 HRP20161158T1 HRP20161158TT HRP20161158T HRP20161158T1 HR P20161158 T1 HRP20161158 T1 HR P20161158T1 HR P20161158T T HRP20161158T T HR P20161158TT HR P20161158 T HRP20161158 T HR P20161158T HR P20161158 T1 HRP20161158 T1 HR P20161158T1
- Authority
- HR
- Croatia
- Prior art keywords
- ifn
- lower respiratory
- ili
- influenza
- disease
- Prior art date
Links
- 108090000467 Interferon-beta Proteins 0.000 title claims 12
- 210000002345 respiratory system Anatomy 0.000 title claims 8
- 206010022000 influenza Diseases 0.000 title claims 6
- 102000003996 Interferon-beta Human genes 0.000 title claims 2
- 229960001388 interferon-beta Drugs 0.000 title claims 2
- 102100026720 Interferon beta Human genes 0.000 claims 10
- 206010022004 Influenza like illness Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims 4
- 239000000443 aerosol Substances 0.000 claims 4
- 239000002911 sialidase inhibitor Substances 0.000 claims 4
- 206010011224 Cough Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030500 lower respiratory tract disease Diseases 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical group CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
1. Interferon-β (IFN-β) za liječenje bolesti donjeg dišnog sustava koja se razvila tijekom ili nakon dijagnosticiranja bolesti gripe (ILI), pri čemu je navedeni tretman pomoću aerosol apliciranja navedenog lijeka do donjeg dišnog sustava; pri čemu je ILI definiran kao (a) groznica >37,8°C plus dva od slijedećih simptoma: glavobolja, kašalj, upala grla i mijalgija i/ili (b) potvrđena gripa; pri čemu dijagnosticirani ILI označava bolest u kojoj su simptomi postali očiti tijekom najmanje 48 sati; pri čemu je bolest donjeg dišnog sustava uzrokovana gripom; i pri čemu je IFN-β apliciran do donjeg dišnog sustava pomoću aerosola za najmanje 48 sati nakon što su simptomi ILI postali očiti.
2. IFN-β za uporabu prema patentnom zahtjevu 1 koji sadrži sekvencu: (a) humanog IFN-β1a (SEK ID BR : 2); ili (b) humanog IFN-β1b (SEK ID BR : 4).
3. IFN-β za uporabu prema bilo kojem od prethodnih zahtjeva u kombinaciji s inhibitorom neuraminidaze.
4. IFN-β za uporabu prema patentnom zahtjevu 3, gde je inhibitor neuraminidaze lokalno aktivan.
5. IFN-β za uporabu prema patentnom zahtjevu 3 ili patentnom zahtjevu 4, gde je inhibitor neuraminidaze zanamivir.
6. IFN-β za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time da pacijent boluje od astme i/ ili COPD.
7. IFN-β za uporabu prema bilo kojem od patentnih zahtjeva 1-6, gdje pacijent ima više od 60 godina starosti.
8. Proizvod za uporabu u liječenju bolesti donjeg dišnog sustava koja se razvila tijekom ili nakon dijagnosticiranja bolesti poput gripe (ILI) sadrži (i) IFN-β i (ii) inhalirani inhibitor neuraminidaze za istovremenu, odvojenu ili sekvencijalnu aerosol primjenu do donjeg dišnog sustava; pri čemu je ILI definiran kao (a) groznica >37,8°C plus dva od slijedećih simptoma: glavobolja, kašalj, upala grla i mijalgija i/ili (b) potvrđena gripa; pri čemu dijagnosticirana ILI označava bolest u kojoj su simptomi postali očiti tijekom najmanje 48 sati; pri čemu je bolest donjeg dišnog sustava uzrokovana gripom; i pri čemu je IFN-β apliciran do donjeg dišnog sustava pomoću aerosola tijekom najmanje 48 sati nakon što su simptomi ILI postali očiti.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1004144.0A GB201004144D0 (en) | 2010-03-12 | 2010-03-12 | Therapy for influenza like illness |
| GBGB1008114.9A GB201008114D0 (en) | 2010-05-17 | 2010-05-17 | Therapy for influenza like illness |
| EP11730046.7A EP2544705B1 (en) | 2010-03-12 | 2011-03-10 | Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza |
| PCT/GB2011/050480 WO2011110861A2 (en) | 2010-03-12 | 2011-03-10 | Therapy for influenza like illness |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161158T1 true HRP20161158T1 (hr) | 2016-11-18 |
Family
ID=44563925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161158TT HRP20161158T1 (hr) | 2010-03-12 | 2016-09-08 | Interferon beta za liječenje bolesti donjeg dišnog sustava izazvane gripom |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9421243B2 (hr) |
| EP (1) | EP2544705B1 (hr) |
| JP (1) | JP5926200B2 (hr) |
| CN (2) | CN107050431A (hr) |
| CA (1) | CA2792727C (hr) |
| CY (1) | CY1117985T1 (hr) |
| DK (1) | DK2544705T3 (hr) |
| ES (1) | ES2592528T3 (hr) |
| HR (1) | HRP20161158T1 (hr) |
| HU (1) | HUE029250T2 (hr) |
| LT (1) | LT2544705T (hr) |
| PL (1) | PL2544705T3 (hr) |
| PT (1) | PT2544705T (hr) |
| RS (1) | RS55154B1 (hr) |
| SI (1) | SI2544705T1 (hr) |
| SM (1) | SMT201600334B (hr) |
| WO (1) | WO2011110861A2 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230338475A1 (en) * | 2020-07-20 | 2023-10-26 | Synairgen Research Limited | USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS |
| GB202014114D0 (en) | 2020-09-08 | 2020-10-21 | Synairgen Res Ltd | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030609A (en) * | 1995-05-19 | 2000-02-29 | Case Western Reserve University | Method and composition for treating paramyxovirus |
| PE20010540A1 (es) * | 1999-07-30 | 2001-05-15 | Procter & Gamble | Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza |
| GB2362884A (en) | 2000-05-30 | 2001-12-05 | Isis Innovation | Extended duration of airway gene therapy |
| AU2004270102B2 (en) * | 2003-05-23 | 2009-10-01 | Pestka Biomedical Laboratories, Inc. | Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections |
| EP1641485A4 (en) | 2003-06-09 | 2009-06-24 | Genome Inst Of Singapore | INHIBITION OF SARS CORONAVIRUS INFECTION USING ANTIVIRAL DRUGS CLINICALLY TESTED |
| CN101001644B (zh) * | 2003-08-28 | 2011-09-21 | 辉阳科技美国公司 | 空间构象改变的干扰素及其应用 |
| GB0518425D0 (en) * | 2005-09-09 | 2005-10-19 | Imp College Innovations Ltd | Methods |
| GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| CN1927388B (zh) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物 |
| CN1927389B (zh) * | 2004-09-10 | 2012-11-14 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物在制备预防或/和治疗呼吸道病毒感染疾病药物方面的应用 |
| US20080292586A1 (en) * | 2005-02-04 | 2008-11-27 | Karen Jervis | Method and Use of Interferon Compositions For the Treatment of Avian Influenza |
| JP5172679B2 (ja) | 2005-09-09 | 2013-03-27 | インペリアル イノベーションズ リミテッド | 呼吸器疾患の治療のためのインターフェロン−λ療法 |
| US20080260690A1 (en) * | 2005-11-18 | 2008-10-23 | Ares Trading S.A. | Interferon in Influenza |
| GB0609410D0 (en) * | 2006-05-12 | 2006-06-21 | Viragen Inc | Method for the production of a type 1 interfemon in a transgenic avian |
| CA2589613A1 (en) * | 2007-05-18 | 2008-11-18 | Synairgen Plc | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
| WO2008143892A1 (en) * | 2007-05-18 | 2008-11-27 | New York University | Method of treating tuberculosis with interferons |
-
2011
- 2011-03-10 CA CA2792727A patent/CA2792727C/en active Active
- 2011-03-10 WO PCT/GB2011/050480 patent/WO2011110861A2/en active Application Filing
- 2011-03-10 HU HUE11730046A patent/HUE029250T2/en unknown
- 2011-03-10 PT PT117300467T patent/PT2544705T/pt unknown
- 2011-03-10 US US13/583,976 patent/US9421243B2/en active Active
- 2011-03-10 SI SI201130956A patent/SI2544705T1/sl unknown
- 2011-03-10 CN CN201710145580.7A patent/CN107050431A/zh active Pending
- 2011-03-10 LT LTEP11730046.7T patent/LT2544705T/lt unknown
- 2011-03-10 EP EP11730046.7A patent/EP2544705B1/en active Active
- 2011-03-10 ES ES11730046.7T patent/ES2592528T3/es active Active
- 2011-03-10 PL PL11730046T patent/PL2544705T3/pl unknown
- 2011-03-10 RS RS20160753A patent/RS55154B1/sr unknown
- 2011-03-10 CN CN2011800135925A patent/CN102883741A/zh active Pending
- 2011-03-10 DK DK11730046.7T patent/DK2544705T3/en active
- 2011-03-10 JP JP2012557607A patent/JP5926200B2/ja active Active
-
2016
- 2016-09-08 HR HRP20161158TT patent/HRP20161158T1/hr unknown
- 2016-09-12 CY CY20161100897T patent/CY1117985T1/el unknown
- 2016-09-21 SM SM201600334T patent/SMT201600334B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201600334B (it) | 2016-11-10 |
| EP2544705B1 (en) | 2016-08-31 |
| CN102883741A (zh) | 2013-01-16 |
| WO2011110861A2 (en) | 2011-09-15 |
| PT2544705T (pt) | 2016-09-21 |
| US9421243B2 (en) | 2016-08-23 |
| SI2544705T1 (sl) | 2016-11-30 |
| RS55154B1 (sr) | 2017-01-31 |
| ES2592528T3 (es) | 2016-11-30 |
| JP5926200B2 (ja) | 2016-05-25 |
| WO2011110861A3 (en) | 2011-11-24 |
| US20130064792A1 (en) | 2013-03-14 |
| CY1117985T1 (el) | 2017-05-17 |
| PL2544705T3 (pl) | 2017-02-28 |
| DK2544705T3 (en) | 2016-09-19 |
| LT2544705T (lt) | 2016-10-10 |
| HUE029250T2 (en) | 2017-04-28 |
| JP2013522282A (ja) | 2013-06-13 |
| CA2792727C (en) | 2019-06-04 |
| CA2792727A1 (en) | 2011-09-15 |
| EP2544705A2 (en) | 2013-01-16 |
| CN107050431A (zh) | 2017-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gu et al. | The mechanism behind influenza virus cytokine storm | |
| Chakraborty et al. | COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials | |
| Abdolvahab et al. | Potential role of interferons in treating COVID-19 patients | |
| Michaelis et al. | Novel swine-origin influenza A virus in humans: another pandemic knocking at the door | |
| Van Reeth | Cytokines in the pathogenesis of influenza | |
| Jiang et al. | Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines | |
| JP2015534562A5 (hr) | ||
| Wang et al. | Clinical features of three avian influenza H7N 9 virus‐infected patients in S hanghai | |
| Rajagopal et al. | Pandemic (avian) influenza | |
| Singh et al. | Potential bioactive molecules from natural products to combat against coronavirus | |
| Shankaran et al. | Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy | |
| JP2013510169A5 (hr) | ||
| JP2014532722A5 (hr) | ||
| Porteous et al. | Resurgence of vaccine-preventable diseases in the United States: anesthetic and critical care implications | |
| HRP20161158T1 (hr) | Interferon beta za liječenje bolesti donjeg dišnog sustava izazvane gripom | |
| JP2016517446A5 (hr) | ||
| Verma et al. | A review on coronavirus disease and potentially active drugs targeting coronavirus | |
| Tok et al. | An updated review on Covid-19 with special reference to structural elucidation and functional properties | |
| Choi et al. | Clinical practice guideline for antiviral treatment and chemoprophylaxis of seasonal influenza | |
| Aoki et al. | Guidance for practitioners on the use of antiviral drugs to control influenza outbreaks in long-term care facilities in Canada, 2014–2015 season | |
| RU2014136096A (ru) | Лекарственное средство для лечения и профилактики заболеваний верхних и нижних дыхательных путей различной этиологии, его применение и метод лечения на его основе | |
| Arsoy et al. | Mysterious side of COVID-19 pandemic: Children | |
| ÇEVİKELLİ YAKUT et al. | What we know about COVID-19 and its treatment. | |
| Li et al. | Existing drug treatments cannot significantly shorten the clinical cure time of children with COVID-19 | |
| EA201201362A1 (ru) | Фармацевтический аэрозольный состав ингибиторов протеаз и его получение |